Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Millard

Showing results (101-110 of 104) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 104 results.
JMIR Research Protocols|February 20, 2025
High-Intensity Interval Training for Individuals With Isolated Impaired Fasting Glucose: Protocol for a Proof-of-Concept Randomized Controlled TrialSathish Thirunavukkarasu, Thomas R Ziegler, Mary Beth Weber, et al.
Cancer Immunology Research|January 6, 2025
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor ControlSara Majocchi, Pauline Lloveras, Lise Nouveau, et al.
Cancer|January 22, 2013
A Web-based communication aid for patients with cancer: the CONNECT StudyNeal J Meropol, Brian L Egleston, Joanne S Buzaglo, et al.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
Pageof 11

Showing results (101-110 of 104) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 104 results.
JMIR Research Protocols|February 20, 2025
High-Intensity Interval Training for Individuals With Isolated Impaired Fasting Glucose: Protocol for a Proof-of-Concept Randomized Controlled TrialSathish Thirunavukkarasu, Thomas R Ziegler, Mary Beth Weber, et al.
Cancer Immunology Research|January 6, 2025
NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor ControlSara Majocchi, Pauline Lloveras, Lise Nouveau, et al.
Cancer|January 22, 2013
A Web-based communication aid for patients with cancer: the CONNECT StudyNeal J Meropol, Brian L Egleston, Joanne S Buzaglo, et al.
The Lancet. Respiratory Medicine|November 7, 2022
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trialsNicole Mayer-Hamblett, Felix Ratjen, Renee Russell, et al.
Pageof 11